Immutep receives A$3.6 million R&D tax incentive

Immutep Limited (ASX:IMM) has received a €2,194,918 (~A$3,627,980) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d'Impôt Recherche scheme (CIR). The cash payment is provided in respect of expenditure incurred on eligible R&D activities conducted in the European Union in the 2023 calendar year.

Immutep's utilization of the R&D tax incentive

The funds received from the French Government's R&D tax incentive will be utilized to support the ongoing and planned global clinical development of eftilagimod alpha and IMP761. Immutep also qualifies for cash rebates from the Australian Federal Government's R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia.

Immutep's R&D tax incentive and future plans

Immutep Limited (ASX:IMM) has received a €2,194,918 (~A$3,627,980) cash payment as an R&D tax incentive from the French Government. This payment will support the ongoing and planned global clinical development of eftilagimod alpha and IMP761. The company also qualifies for cash rebates from the Australian Federal Government's R&D tax incentive program. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximize value for shareholders.